Alzheimer's disease market set for double-digit growth
The global Alzheimer’s disease (AD) market, worth $2.9 billion in 2016, is set to reach $14.8 billion by 2026, rising at a compound annual growth rate (CAGR) of 17.5%, across the 7 seven main markets (7MM: USA, Japan, France, Germany, Italy, Spain, and UK.).
According to business information and analytics provider GlobalData’s latest report: ‘PharmaPoint: Alzheimer’s Disease – Global Drug Forecast and Market Analysis to 2026’ focuses on the substantial landscape change that the AD market is expected to undergo in the next 10 years.
Market growth will be driven by the introduction of 20 new drug candidates, some of which have shown potential to prevent or slow down the progression of AD. These include passive immunotherapies aducanumab from Biogen (Nasdaq: BIIB), gantenerumab from Roche (ROG: SIX), and crenezumab from Roche and AC Immune (Nasdaq: ACIU), which are expected to have significant uptake in the 7MM.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze